Publication

Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.

Journal Paper/Review - Sep 1, 2022

Units
PubMed
Doi
Contact

Citation
Patel K, Huo Y, Jao J, Powis K, Williams P, Kacanek D, Yee L, Chadwick E, Shiau S, Jacobson D, Brummel S, Sultan-Beyer L, Kahlert C, Zash R, Seage G, ĀăąĆĉČĎ Ā. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States. N Engl J Med 2022; 387:799-809.
Type
Journal Paper/Review (English)
Journal
N Engl J Med 2022; 387
Publication Date
Sep 1, 2022
Issn Electronic
1533-4406
Pages
799-809
Brief description/objective

Data on the effectiveness and safety of dolutegravir-based antiretroviral therapy (ART) for human immunodeficiency virus type 1 (HIV-1) infection in pregnancy as compared with other ART regimens commonly used in the United States and Europe, particularly when initiated before conception, are limited.